Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Celecoxib helps prevent restenosis and appears safe

17.08.2007
Adjunctive use of the COX-2 inhibitor celcoxib after stent implantation in patients with coronary artery disease is safe and can reduce the need for revascularisation of the target lesion, conclude authors of an Article published in this week’s Cardiology Special Issue of The Lancet.

But an accompanying Comment warns that clinical trials suggest long-term use of celecoxib can expose patients to an additional risk of heart attack.

Dr Hyo-Soo Kim, Seoul National University Hospital, Seoul, South Korea and colleagues have published the results of the COREA-TAXUS trial, which aimed to test whether the COX-2 inhibitor celecoxib could prevent the formation of smooth muscle tissue (neointima) within stents, which can lead to narrowing and eventually re-blockage of the lumen of the stent (restenosis).

They studied 274 patients, all of whom were given aspirin (100mg) daily and clopidogrel (75mg daily). Of these, 136 were randomly assigned to receive celecoxib (400mg before the stent implantation, and then 200mg twice daily for 6 months after the procedure). The in-stent lumen diameter of all patients was measured using a coronary angiography six months after stent implantation.

The researchers found that the average reduction on in-stent luminal diameter was 0.49mm in the celecoxib group and 0.75mm in the control group, meaning that celecoxib reduced the luminal reduction by 35%. There was also a decreased need for target-lesion revascularisation in the celecoxib group.

The authors say: “These data suggest that the adjunctive use of celecoxib for 6 months after stent implantation in patients with coronary artery is safe.” They add that unlike with another COX-2 inhibitor rofecoxib, celecoxib does not increase the risk of cardiovascular events. They say: “Administration of celecoxib for 6 months does not seem to increase the risk of adverse cardiac events in the intermediate term when used with dual anti-platelet therapy. We will be interested to see the 2-5 year follow-up results of this cohort.”

In the accompanying Comment, Drs Francesco Pelliccia and Vincenzo Pasceri, Interventional Cardiology Unit, Ospedale San Filippo Neri, Rome, Italy say that the safety of celecoxib needs to be confirmed by studies to assess risk of heart attack and cardiac death, and that gastrointestinal tolerability of celecoxib in combination with aspirin and clopidogrel could also be a drawback.

However the Comment authors conclude: “The study by Koo and colleagues underscores that systemic therapy might still have a role in prevention of restenosis, even in the era of drug-eluting stents.”

Tony Kirby | alfa
Further information:
http://www.thelancet.com/webfiles/images/clusters/thelancet/press_office/celecoxib.pdf

More articles from Health and Medicine:

nachricht Chances to treat childhood dementia
24.07.2017 | Julius-Maximilians-Universität Würzburg

nachricht World first: Massive thrombosis removed during early pregnancy
20.07.2017 | Universitätsspital Bern

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: 3-D scanning with water

3-D shape acquisition using water displacement as the shape sensor for the reconstruction of complex objects

A global team of computer scientists and engineers have developed an innovative technique that more completely reconstructs challenging 3D objects. An ancient...

Im Focus: Manipulating Electron Spins Without Loss of Information

Physicists have developed a new technique that uses electrical voltages to control the electron spin on a chip. The newly-developed method provides protection from spin decay, meaning that the contained information can be maintained and transmitted over comparatively large distances, as has been demonstrated by a team from the University of Basel’s Department of Physics and the Swiss Nanoscience Institute. The results have been published in Physical Review X.

For several years, researchers have been trying to use the spin of an electron to store and transmit information. The spin of each electron is always coupled...

Im Focus: The proton precisely weighted

What is the mass of a proton? Scientists from Germany and Japan successfully did an important step towards the most exact knowledge of this fundamental constant. By means of precision measurements on a single proton, they could improve the precision by a factor of three and also correct the existing value.

To determine the mass of a single proton still more accurate – a group of physicists led by Klaus Blaum and Sven Sturm of the Max Planck Institute for Nuclear...

Im Focus: On the way to a biological alternative

A bacterial enzyme enables reactions that open up alternatives to key industrial chemical processes

The research team of Prof. Dr. Oliver Einsle at the University of Freiburg's Institute of Biochemistry has long been exploring the functioning of nitrogenase....

Im Focus: The 1 trillion tonne iceberg

Larsen C Ice Shelf rift finally breaks through

A one trillion tonne iceberg - one of the biggest ever recorded -- has calved away from the Larsen C Ice Shelf in Antarctica, after a rift in the ice,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Closing the Sustainability Circle: Protection of Food with Biobased Materials

21.07.2017 | Event News

»We are bringing Additive Manufacturing to SMEs«

19.07.2017 | Event News

The technology with a feel for feelings

12.07.2017 | Event News

 
Latest News

Ultrathin device harvests electricity from human motion

24.07.2017 | Power and Electrical Engineering

Scientists announce the quest for high-index materials

24.07.2017 | Materials Sciences

ADIR Project: Lasers Recover Valuable Materials

24.07.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>